A randomised, double-blind study of itraconazole versus placebo in the treatment and prevention of oral or oesophageal candidosis in patients with HIV infection

International Journal of Clinical Practice

Volumn 53, Issue 5, 1999, Pages 349-352

  Smith, D ^b   Midgley, J ^a   Gazzard, B ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; PLACEBO;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGUS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LETHARGY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; THRUSH; VOMITING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, ORAL; DOUBLE-BLIND METHOD; ESOPHAGEAL DISEASES; FEMALE; HIV INFECTIONS; HUMANS; ITRACONAZOLE; MALE; PLACEBO EFFECT; PLACEBOS; TREATMENT OUTCOME;

EID: 0032807669     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patents: frequencies, associations and trends. AIDS 1987; 1: 175-82.
2. Montaner JSG, Le T, Hogg R et al. The changing spectrum of AIDS index diseases in Canada. AIDS 1994; 8: 693-696.
3. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-272.
4. Hardin TC, Graybill JR, Fetchick R et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32: 1310-1313.
5. Smith DE, Midgley J, Allan M et al. Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991; 5: 1367-1371.
6. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbid Mortal Wkly Rec 1987; 36(suppl): 1-5.
7. Leen CLS, Dunbar EM, Ellis ME et al. Once-weekly fluconazole to prevent recurrences of oropharyngeal candidosis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990; 21: 55-60.
8. Newton JA, Tasker SA, Bone WD et al. Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact of the incidence of disseminated crypotococcal infection. AIDS 1995; 9: 1286-1287.
9. Heald AE, Cox GM, Schell WA et al. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 1996; 10: 263-268.